AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Disseminated M-avium complex infection in the Swiss HIV cohort study: Declining incidence, improved prognosis and discontinuation of maintenance therapy
Authors: Rossi, M Flepp, M Telenti, A Schiffer, V Egloff, N Bucher, H Vernazza, P Bernasconi, E Weber, R Rickenbach, M Furrer, H
Citation: M. Rossi et al., Disseminated M-avium complex infection in the Swiss HIV cohort study: Declining incidence, improved prognosis and discontinuation of maintenance therapy, SWISS MED W, 131(31-32), 2001, pp. 471-477
Chronic watery diarrhea due to co-infection with Cryptosporidium spp and Cyclospora cayetanensis in a Swiss AIDS patient traveling in Thailand
Authors: Egloff, N Oehler, T Rossi, M Nguyen, XM Furrer, H
Citation: N. Egloff et al., Chronic watery diarrhea due to co-infection with Cryptosporidium spp and Cyclospora cayetanensis in a Swiss AIDS patient traveling in Thailand, J TRAVEL M, 8(3), 2001, pp. 143-145
Clinical manifestations and predictors of survival in AIDS patients with disseminated Mycobacterium avium infection
Authors: Roos, F Flepp, M Figueras, G Bodmer, T Furrer, H
Citation: F. Roos et al., Clinical manifestations and predictors of survival in AIDS patients with disseminated Mycobacterium avium infection, EUR J CL M, 20(6), 2001, pp. 428-430
Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study
Authors: Furrer, H Opravil, M Rossi, M Bernasconi, E Telenti, A Bucher, H Schiffer, V Boggian, K Rickenbach, M Flepp, M Egger, M
Citation: H. Furrer et al., Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study, AIDS, 15(4), 2001, pp. 501-507
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study
Authors: Friedl, AC Ledergerber, B Flepp, M Hirschel, B Telenti, A Furrer, H Bucher, HC Bernasconi, E Weber, R
Citation: Ac. Friedl et al., Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study, AIDS, 15(14), 2001, pp. 1793-1800
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Authors: Fellay, J Boubaker, K Ledergerber, B Bernasconi, E Furrer, H Battegay, M Hirschel, B Vernazza, P Francioli, P Greub, G Flepp, M Telenti, A
Citation: J. Fellay et al., Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study, LANCET, 358(9290), 2001, pp. 1322-1327
Increased risk of wasting syndrome in HIV-infected travellers: prospectivemulticentre study
Authors: Furrer, H Chan, P Weber, R Egger, M
Citation: H. Furrer et al., Increased risk of wasting syndrome in HIV-infected travellers: prospectivemulticentre study, T RS TROP M, 95(5), 2001, pp. 484-486
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy.
Authors: Ledergerber, B Mocroft, A Reiss, P Furrer, H Kirk, O Bickel, M Uberti-Foppa, C Pradier, C Monforte, AD Schneider, MME Lundgren, JD
Citation: B. Ledergerber et al., Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy., N ENG J MED, 344(3), 2001, pp. 168-174
Stochastic processes in insurance and finance
Authors: Embrechts, P Frey, R Furrer, H
Citation: P. Embrechts et al., Stochastic processes in insurance and finance, HANDB STAT, 19, 2001, pp. 365-412
Prevalence and clinical significance of splenomegaly in asymptomatic humanimmunodeficiency virus type 1-infected adults
Authors: Furrer, H
Citation: H. Furrer, Prevalence and clinical significance of splenomegaly in asymptomatic humanimmunodeficiency virus type 1-infected adults, CLIN INF D, 30(6), 2000, pp. 943-945
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Authors: Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME
Citation: H. Masur et al., 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, CLIN INF D, 30, 2000, pp. S29-S65
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
Authors: Yerly, S Kaiser, L Perneger, TV Cone, RW Opravil, M Chave, JP Furrer, H Hirschel, B Perrin, L
Citation: S. Yerly et al., Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia, AIDS, 14(3), 2000, pp. 243-249
Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study
Authors: Furrer, H Telenti, A Rossi, M Ledergerber, B
Citation: H. Furrer et al., Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study, AIDS, 14(10), 2000, pp. 1409-1412
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the SwissHIV Cohort Study
Authors: Greub, G Ledergerber, B Battegay, M Grob, P Perrin, L Furrer, H Burgisser, P Erb, P Boggian, K Piffaretti, JC Hirschel, B Janin, P Francioli, P Flepp, M Telenti, A
Citation: G. Greub et al., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the SwissHIV Cohort Study, LANCET, 356(9244), 2000, pp. 1800-1805
Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
Authors: Furrer, H Opravil, M Bernasconi, E Telenti, A Egger, M
Citation: H. Furrer et al., Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis, LANCET, 355(9222), 2000, pp. 2217-2218
Advice to HIV-infected persons travelling to (sub)tropical destinations
Authors: Oehler, T Buchel, B Hatz, C Furrer, H
Citation: T. Oehler et al., Advice to HIV-infected persons travelling to (sub)tropical destinations, SCHW MED WO, 130(27-28), 2000, pp. 1041-1050
The effect of diagenesis on oxygen isotope ratios of biogenic phosphates
Authors: Sharp, ZD Atudorei, V Furrer, H
Citation: Zd. Sharp et al., The effect of diagenesis on oxygen isotope ratios of biogenic phosphates, AM J SCI, 300(3), 2000, pp. 222-237
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?
Authors: Bassetti, S Battegay, M Furrer, H Rickenbach, M Flepp, M Kaiser, L Telenti, A Vernazza, PL Bernasconi, E Sudre, P
Citation: S. Bassetti et al., Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?, J ACQ IMM D, 21(2), 1999, pp. 114-119
Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: A countrywide 9-year cohort study
Authors: Sudre, P Pfyffer, GE Bodmer, T Prod'hom, G Furrer, H Bassetti, S Bernasconi, E Matter, L Telenti, A Strassle, A Jacques, JP Weber, R
Citation: P. Sudre et al., Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: A countrywide 9-year cohort study, INFECTION, 27(6), 1999, pp. 323-330
HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cellresponses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decreasein viraemia
Authors: Wendland, T Furrer, H Vernazza, PL Frutig, K Christen, A Matter, L Malinverni, R Pichler, WJ
Citation: T. Wendland et al., HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cellresponses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decreasein viraemia, AIDS, 13(14), 1999, pp. 1857-1862
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Authors: Ledergerber, B Egger, M Opravil, M Telenti, A Hirschel, B Battegay, M Vernazza, P Sudre, P Flepp, M Furrer, H Francioli, P Weber, R
Citation: B. Ledergerber et al., Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study, LANCET, 353(9156), 1999, pp. 863-868
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study
Authors: Ledergerber, B Erard, V Weber, R Hirschel, B Furrer, H Battegay, M Vernazza, P Bernasconi, E Opravil, M Kaufmann, D Sudre, P Francioli, P Telenti, A
Citation: B. Ledergerber et al., AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study, J AM MED A, 282(23), 1999, pp. 2220-2226
Excessive watery diarrhoea and pronounced fatigue due to Cyclospora cayetanensis infection in an HIV-infected traveller returning from the tropics
Authors: Mosimann, M Nguyen, XM Furrer, H
Citation: M. Mosimann et al., Excessive watery diarrhoea and pronounced fatigue due to Cyclospora cayetanensis infection in an HIV-infected traveller returning from the tropics, SCHW MED WO, 129(33), 1999, pp. 1158-1161
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
Authors: Furrer, H Egger, M Opravil, M Bernasconi, E Hirschel, B Battegay, M Telenti, A Vernazza, PL Rickenbach, M Flepp, M Malinverni, R
Citation: H. Furrer et al., Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy, N ENG J MED, 340(17), 1999, pp. 1301-1306
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Authors: Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME Kaplan, JE
Citation: H. Masur et al., 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, ANN INT MED, 131(11), 1999, pp. 873-908
Risultati: 1-25 | 26-26